Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
C4 Therapeutics ( (CCCC) ) just unveiled an update.
On January 14, 2025, C4 Therapeutics announced its anticipated milestones for the year, highlighting continued progress in its clinical portfolio of degrader medicines targeting high unmet needs in oncology. The company showcased its achievements in 2024, including advancements in clinical trials for cemsidomide and CFT1946, with significant data expected in the second half of 2025. C4T also announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference and reported a strong cash position to support operations into 2027. These developments position C4T as a promising player in the biopharmaceutical industry, focusing on innovative treatments for oncology patients.
More about C4 Therapeutics
C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science. It develops small-molecule medicines designed to degrade disease-causing proteins, particularly for difficult-to-treat diseases, using its proprietary TORPEDO® platform. C4T is committed to transforming patients’ lives by addressing drug resistance and undruggable targets.
YTD Price Performance: -4.37%
Average Trading Volume: 1,433,580
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $258.7M
For a thorough assessment of CCCC stock, go to TipRanks’ Stock Analysis page.
